1.Superficial Angiomyxoma of the Eyelid. A Case Report and Review of the Literature
Nadzrin Md Yusof ; Noraini Mohd Dusa ; Norhafizah Mohtarrudin ; Razana Mohd Ali
Malaysian Journal of Medicine and Health Sciences 2020;16(Supp 9, November):134-136
Superficial angiomyxoma (SA) is an angiomyxoid cutaneous tumour. It has predilection for the head and
neck, torso, limbs and genital tract. Our case is a 27-year-old female, presented with painless right medial
canthal mass for two years. It was associated with tearing when the lesion grew larger. We received a
nodular brownish tissue measuring 25x20x15mm with homogenous brownish cut surface. Microscopically,
the tumour was partially circumscribed, exhibiting bland stellate to spindle cells of moderate cellularity with
pale eosinophilic cytoplasm, indistinct border, in a loose collagenous myxoid matrix with numerous blood
vessels of different calibre. The lesional cells were present at the resected margin and were nonreactive
towards CD34, SMA and S100. SA of the eyelid is sometimes mistaken clinically as dermoid cyst or lipoma.
Reports have shown increased risks of local recurrence following incomplete excision. Close association
with Carney’s complex is an important feature. Careful clinicopathologic correlation and proper investigations
are needed for optimal patient care.
2. Anti-breast cancer properties and toxicity of Dillenia suffruticosa root aqueous extract in BALB/c mice
Latifah Saiful YAZAN ; Yong Sze ONG ; Jhi Biau FOO ; Yin Sim TOR ; Latifah Saiful YAZAN ; Nur Elena ZAABA ; Razana Mohd ALI
Asian Pacific Journal of Tropical Biomedicine 2015;5(12):1018-1026
Objective: To determine the anti-breast cancer activities and the safety oral consumption of Dillenia suffruticosa root aqueous extract (DRAE) in BALB/c mice. Methods: In the anti-breast cancer study, female BALB/c mice were divided into five groups (n = 12), which were (1) positive control (with breast cancer, untreated), (2) negative control (without breast cancer, untreated) and other three groups of mice with breast cancer treated with 1000, 500 and 250 mg/kg of DRAE, respectively, by oral gavage for 28 days. All mice except from the negative control group were injected into the mammary fat pad with 4T1 cells (1 × 10